Key Regulatory Information - Wegovy
Wegovy® is a prescription-only medication.
In accordance with current French regulations, this medication cannot be sold online.
However, you can place a reservation request on our website and pick up the product at the Mailloles pharmacy located in Perpignan, in the Pyrénées-Orientales region of France, provided you have a valid prescription for this treatment.
Dispensation is always contingent upon our pharmacy team verifying that the prescription is valid.
For complete indications, warnings, contraindications, and side effects, please consult the official package insert and ask your doctor or pharmacist for advice.
Therapeutic Indications for Wegovy
Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for the chronic management of weight in:
- Patients with obesity (BMI ≥ 30 kg/m²)
- Patients who are overweight (BMI ≥ 27 kg/m²) with at least one associated risk factor (high blood pressure, dyslipidemia, type 2 diabetes, etc.)
This treatment is part of acomprehensive -based care plan supervised by a healthcare professional.
Mechanism of Action of Semaglutide
The active ingredient in Wegovy® is semaglutide, a GLP-1 (Glucagon-Like Peptide-1) analog.
GLP-1 is a hormone involved in:
- Appetite regulation
- The feeling of fullness
- Blood glucose control
Semaglutide acts on the brain centers that regulate eating, increasing the feeling of fullness and reducing hunger. It also helps improve metabolic control in eligible patients.
Wegovy Dosage and Administration
Wegovy® is administered by subcutaneous injection once a week, on the same day each week.
Possible injection sites:
Treatment begins at 0.25 mg once a week, with a gradual increase according to the prescribed medical regimen, up to a maintenance dose of 2.4 mg per week.
This gradual increase is intended to improve gastrointestinal tolerance.
The FlexTouch® pre-filled pen allows for simple and precise administration. The injection takes about 5 to 10 seconds.
It is essential to strictly follow the doctor’s instructions.
Precautions for Use with GLP-1 Analog s and Contraindications
Wegovy® is contraindicated in certain situations, including:
- Hypersensitivity to semaglutide
- Pregnancy
- Breastfeeding
Special Precautions:
- Tell your doctor if you havea history of pancreatitis
- Report any r concomitant treatments
- Consult a doctor if you experience persistent abdominal pain
- Stay well-hydrated
The most commonly reported side effects are gastrointestinal (nausea, vomiting, diarrhea).
For complete information, refer to the official package insert.
Additional Regulatory Information
- Prescription-only medication
- Available only at pharmacies
- Read the package insert carefully before use
- Do not share the pen
- Store in the refrigerator (2–8 °C) before opening
- Do not freeze
Medical Summary of the Product
Wegovy® (semaglutide) is an injectable medication indicated for the chronic management of weight in obese or overweight patients with risk factors. It acts as a GLP-1 analog, increasing satiety and contributing to weight loss as part of a supervised medical program.
Pharmacist’s Advice Regarding Wegovy
Wegovy® is not a medication intended for cosmetic purposes. It is a treatment indicated for the medical management of obesity and overweight conditions with comorbidities.
Its effectiveness depends on:
- Adherence to the medical protocol
- A balanced diet
- Regular physical activity
- Regular medical follow-up
Any change in dosage must be determined by the prescribing physician.
Frequently Asked Questions
Can Wegovy® be purchased online?
No. Online sales are not permitted. The medication can be reserved and picked up at a pharmacy with a valid prescription.
Who is this treatment intended for?
For patients who are obese or overweight with comorbidities, as prescribed by a doctor.
How long does treatment last?
The duration is determined by the doctor based on the clinical response and treatment goals.
Does Wegovy® replace a diet?
No. It must be combined with an appropriate diet and regular physical activity.